Archives
-
Angiotensin Peptides and SARS-CoV-2 Spike Binding
2026-08-22
The 2025 study shows that naturally occurring angiotensin fragments can enhance SARS-CoV-2 spike-protein binding to host receptors, with effects determined by peptide length, terminal sequence, and tyrosine modification. Its antibody-based binding design provides a useful framework for connecting renin-angiotensin system research with viral receptor biology while emphasizing that biochemical binding is not equivalent to demonstrated infection or clinical risk.
-
Deferoxamine Mesylate in Ferroptosis Workflows
2026-08-22
Deferoxamine mesylate gives researchers a practical way to manipulate labile iron while separating iron-dependent lipid damage from plasma-membrane execution events. This guide shows how to use it as a ferroptosis rescue control, hypoxia-mimetic reagent, and oxidative stress protection tool without confusing chelation with TMEM16F inhibition.
-
Angiotensin I/II (1-5): RAS Workflow Guide
2026-08-21
Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for controlled renin-angiotensin system research involving blood pressure, renal, and aldosterone-related readouts. It is intended for cardiovascular and renal workflows, not general peptide-signaling studies, and its water insolubility requires deliberate solvent, vehicle, and storage controls.
-
RNAi Screen Reveals SARS-CoV-2 Release Factors
2026-08-20
Kerr et al. developed an arrayed, druggable-genome RNA interference screen that measures SARS-CoV-2 production at multiple stages, reducing the bias toward early replication factors. The study identifies Rab11a-linked vesicular transport as a conserved proviral pathway and shows that CDK9 inhibitor-73 can block viral release, supporting further investigation of host-directed antiviral mechanisms.
-
Baicalein in Redox-Aware Cancer Assays
2026-08-20
Baicalein is a 12-LOX-inhibiting flavonoid for dissecting cancer, apoptosis, and inflammatory signaling. This guide builds beyond standard mechanism summaries by showing how to pair pathway engagement with orthogonal redox and cell-selectivity assays.
-
IGFBP2–THBS1 Mechanism in GH-Treated ISS
2026-08-19
The reference study identifies an IGFBP2–THBS1 regulatory axis that links growth hormone treatment to IGF-1 signaling, chondrocyte proliferation, and hypertrophic differentiation in idiopathic short stature. Its perturbation experiments suggest that IGFBP2 is more than a biomarker: it is a functional mediator that may help explain variable responses to somatotropin therapy and guide future mechanistic studies.
-
HyperScript First-Strand cDNA Synthesis Kit for Stress RNA
2026-08-19
Convert structurally challenging or scarce plant RNA into cDNA suited for PCR amplification and qPCR reaction workflows. The HyperScript First-Strand cDNA Synthesis Kit combines primer flexibility with a thermally stable, RNase H-reduced reverse transcriptase for transcriptomics validation and low-copy gene reverse transcription.
-
Biotin-tyramide: Practical TSA Workflows
2026-08-18
Biotin-tyramide converts target-bound HRP into a localized amplification engine for demanding IHC and ISH assays. This guide connects reagent handling, assay controls, and troubleshooting with the spatial-RNA perspective of Halo-seq, while clearly separating compatible imaging workflows from non-interchangeable transcriptome methods.
-
ATP Solution for mRNA and Kinase Workflows
2026-08-18
A ready-to-use 100 mM ATP reagent supports reproducible in vitro transcription, kinase, ligation, and phosphorylation workflows. This practical guide connects ATP-dependent assay control with p21 mRNA–LNP research while separating validated study findings from recommended optimization conditions.
-
Cabozantinib Blocks MLKL Oligomerization in Psoriasis
2026-08-17
The reference study identifies cabozantinib as a repurposed inhibitor of necroptosis that acts at the MLKL oligomerization stage rather than primarily blocking upstream RIPK1 or RIPK3 signaling. In an imiquimod-induced psoriasis model, this mechanism was associated with reduced epidermal hyperplasia and inflammatory cytokine expression, providing a rationale for mechanism-guided drug repositioning screening in inflammatory disease.
-
DAMGO: µ-Opioid Receptor Agonist Workflows
2026-08-17
DAMGO enables controlled interrogation of µ-opioid receptor signaling from membrane assays to central pain circuits. This workflow-oriented guide shows how to connect receptor activation, mechanical hypersensitivity, and tolerance models while avoiding common interpretation and handling errors.
-
Bleomycin Sulfate: From DNA Breaks to Fibrosis
2026-08-16
Bleomycin Sulfate, also recognized in clinical literature as Blenoxane, is more than a DNA-damaging compound. Its metal-dependent oxidative chemistry creates a translational bridge between oncology, pulmonary fibrosis research, and emerging studies of tissue-specific fibrotic signaling.
-
KDM4D–Foxo1 Control of MSC Quiescence
2026-08-15
The 2024 reference study identifies an iron-sensitive KDM4D–PIK3R3–PI3K–Akt–Foxo1 pathway that controls the transition of bone marrow mesenchymal stem cells from quiescence to activation. Its findings connect impaired histone demethylation during iron deficiency with defective MSC mobilization and reduced bone mass, while pathway modulation partially reverses the skeletal phenotype.
-
IWP-2: A Wnt Production Inhibitor for Cell Workflows
2026-08-14
IWP-2 is a potent Wnt production inhibitor for separating ligand-dependent Wnt biology from downstream pathway effects. This guide translates its use across gastric cancer assays and the 6C corneal epithelial culture paradigm, with practical formulation, dosing, readout, and troubleshooting strategies.
-
Brain–Spinal Control of Opioid Hypersensitivity
2026-08-14
Yin et al. identify a lateral parabrachial-to-hypothalamic-to-spinal pathway that controls morphine-induced mechanical hypersensitivity and analgesic tolerance in mice. The study shows that opioid activation can disrupt spinal gate control for mechanically evoked pain, offering a circuit-level explanation for paradoxical pain sensitization during repeated opioid exposure.